Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Chronic gingivostomatitis is a common infection of mouth and gums, leading to drooling and swelling. Sometimes lesions in the mouth resembles the canker sores. This infection is common among children. Increasing incidence of gingivostomatitis is expected to boost the market growth. For instance, according to the Journal of Dental Health, Oral Disorders & Therapy, an article - A Case Report on Symptomatic Primary Herpetic Gingivostomatitis, published in December 2017, states that primary herpetic gingivostomatitis (PHG) is a common pediatric infection usually seen before 6 years of age, which is mostly i.e. 90% caused by Herpes Simplex Virus (HSV) type 1.
The global chronic gingivostomatitis treatment market is estimated to be valued at US$ 12,922.5 million in 2020 and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).
Figure 1. Global Chronic Gingivostomatitis Treatment Market Share (%), by Region, 2020
Major players offering effective products is expected to propel growth of the global chronic gingivostomatitis treatment market
Major players in the market are focused on offering effective products for chronic gingivostomatitis treatment, which is expected to boost the market growth over the forecast period. For instance, GlaxoSmithKline offers Zovirax, a cream with active ingredient, aciclovir, for antiviral treatment for cold sores.
Moreover, other major players also offers generic drugs from other manufacturers. For instance, HERITAGE PHARMS INC offers ZOVIRAX (acyclovir), a suspension, a generic version of the GlaxoSmithKlines’ Zovirax.
Chronic Gingivostomatitis Treatment Market Report Coverage
||Market Size in 2020:
||US$ 12,922.5 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 20,175.2 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: Physical Examination, Microbial Culture, Biopsy, Others.
- By Treatment: Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, Others.
- By End User: Hospitals & Clinics, Academic & Research, Others.
Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc.
- Rising incidence of chronic gingivostomatitis
|Restraints & Challenges:
- Misidentification or diagnosis of chronic gingivostomatitis
Figure 2. Global Chronic Gingivostomatitis Treatment Market Share (%), by Treatment, 2020
Increasing incidence of chronic gingivostomatitis in North America is expected to boost the market growth
North America is expected to hold dominant position in the global chronic gingivostomatitis treatment market, owing to increasing new cases of chronic gingivostomatitis in the region. For instance, according to the Western Journal of Emergency Medicine, an article - Cost of Routine Herpes Simplex Virus Infection Visits to U.S. ED 2006-2013, published in 2018, reports that there were 115,726 number of patient visits with primary diagnosis during 2006-2013 in the U.S.
Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has caused an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global chronic gingivostomatitis treatment market during the forecast period.
Major players operating in the global chronic gingivostomatitis treatment market include Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc.